Welcome to our dedicated page for Tela Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TELA Bio, Inc. filings document a commercial-stage medical technology business centered on soft-tissue reconstruction and the OviTex product portfolio for hernia repair and abdominal wall reconstruction. Form 8-K reports cover operating and financial results, revenue updates, Regulation FD disclosures, material agreements, debt and equity capital structure, and other material events tied to the company's medical technology operations.
Proxy materials and governance-related 8-Ks record board composition, director appointments and resignations, executive compensation matters, stockholder meeting proposals, inducement and equity-award practices, and Nasdaq listing-compliance disclosures for TELA common stock listed on the Nasdaq Global Market.
TELA Bio director Betty Jo Rocchio received new equity awards. She was granted 11,675 restricted stock units of common stock, increasing her direct common stock holdings to 23,600 shares after the award. These units vest on the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control, subject to her continued service.
She also received a stock option covering 17,335 shares of common stock at an exercise price of $0.935 per share, expiring on June 9, 2036. This option vests on the same schedule and service conditions as the restricted stock units.
TELA Bio, Inc. director Joseph H. Capper reported receiving new equity awards in the form of common stock and stock options as compensation. On June 9, 2026 he was granted 11,675 and 11,925 restricted stock units, and options for 17,335 and 17,550 shares at an exercise price of $0.935 per share expiring on June 9, 2036.
The restricted stock units vest over time, either in three equal annual installments beginning on June 9, 2027 or on the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control under the company’s 2019 equity plan, in each case requiring continued service. Following these grants, one line shows 23,600 common shares and another 11,925 common shares held directly.
TELA Bio, Inc. director Joseph H. Capper has filed an initial statement of beneficial ownership as an insider. This Form 3 does not report any insider purchases, sales, option exercises, gifts, or other equity transactions, reflecting only his new status as a reporting person.
TELA Bio director William J. Plovanic received new equity awards as part of his compensation. He was granted 11,675 shares of common stock and a stock option for 17,335 shares at an exercise price of $0.935 per share.
The stock units and the option both vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a Change in Control under TELA Bio’s Amended and Restated 2019 Equity Incentive Plan, in each case subject to his continued service. Following the grant, he directly owns 23,600 common shares and holds the new option for 17,335 underlying shares.
TELA Bio, Inc. director Guido J. Neels filed an initial insider ownership report on Form 3. This filing establishes his status as a director and is a baseline regulatory disclosure. The data provided shows no reported purchases, sales, or other transactions in TELA Bio securities.
TELA Bio director Guido J. Neels reported equity awards rather than open-market trades. On June 9, 2026, he received two grants of Common Stock totaling 23,600 shares after the larger grant and 11,925 shares after the second grant, both at $0.00 per share as compensation awards.
He also received two stock option grants covering 17,335 and 17,550 shares of Common Stock at an exercise price of $0.935 per share, expiring on June 9, 2036. The footnotes state these restricted stock units and options vest over time, generally in annual or monthly installments beginning on or before June 9, 2027, or earlier upon specified events, subject to his continued service.
TELA Bio, Inc. director Thomas Paul filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. This filing lists him as a director but does not report any specific stock transactions or derivative positions in the provided data.
TELA Bio director Paul Thomas reported new equity awards. On June 9, 2026, he received two grants of Common Stock: 11,675 restricted stock units that vest in three equal annual installments starting June 9, 2027, and 11,925 restricted stock units that vest by the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control, in each case subject to continued service.
He also received stock options for 17,335 and 17,550 shares of Common Stock at an exercise price of $0.935 per share, expiring on June 9, 2036. One option grant vests in 36 equal monthly installments beginning on June 9, 2026, and the other vests on the earlier of June 9, 2027, the next annual meeting, or a Change in Control, subject to continued service.
TELA Bio, Inc. director Guy P. Nohra has filed an initial statement of beneficial ownership on Form 3. The data provided show no reportable purchases, sales, gifts, option exercises, or other transactions, and no derivative positions listed at this time.
TELA Bio, Inc. director Guy P. Nohra reported compensation-related equity awards in the form of common stock and stock options. On June 9, 2026, he received 11,675 restricted stock units that vest in three equal annual installments beginning on June 9, 2027, and an additional 11,925 restricted stock units that vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a Change in Control, subject to continued service.
Following these awards, Nohra directly holds 23,600 shares of common stock from one grant and 11,925 shares from the other. He was also granted stock options for 17,335 and 17,550 shares of common stock at an exercise price of $0.935 per share, expiring on June 9, 2036. One option vests in 36 equal monthly installments starting June 9, 2026, and the other vests on the earlier of June 9, 2027, the next annual meeting, or a Change in Control, in each case conditioned on his continued service.